Regulus Therapeutics share price today

(RGLS)

Regulus Therapeutics share price is $1.59 & ₹135.11 as on 21 Dec 2024, 2.30 'hrs' IST

$1.59

▲

0.04

(2.58%)

Market is closed - opens 8 PM, 23 Dec 2024

View live Regulus Therapeutics share price in Dollar and Rupees. Guide to invest in Regulus Therapeutics from India. Also see the sentimental analysis on Indian investors investing in Regulus Therapeutics. Get details on the Indian mutual funds that are investing in Regulus Therapeutics. Get Analyst recommendations and forecasts along with all the Regulus Therapeutics's financials.

Regulus Therapeutics share price movements

Today's Low: $1.51
Today's High: $1.60
$1.59
5.03%
Downside
Day's Volatility :5.62%
Upside
0.63%
52 Weeks Low: $1.08
52 Weeks High: $3.79
$1.59
32.08%
Downside
52 Weeks Volatility :71.5%
Upside
58.05%

Regulus Therapeutics Returns

Period	Regulus Therapeutics Inc	Index (Russel 2000)
3 Months	-3.34%	0.0%
6 Months	-22.44%	0.0%
1 Year	21.37%	0.0%
3 Years	-55.22%	-19.7%

Regulus Therapeutics Key Statistics

in dollars & INR

Previous Close	$1.55
Open	$1.53
Today's High	$1.6
Today's Low	$1.5101
Market Capitalization	$101.5M
Today's Volume	$441.4K
52 Week High	$3.79
52 Week Low	$1.08
Revenue TTM	$5.0M
EBITDA	$-44.3M
Earnings Per Share (EPS)	$-1.02
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-72.36%

How to invest in Regulus Therapeutics from India?

It is very easy for Indian residents to invest directly in Regulus Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Regulus Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Regulus Therapeutics or RGLS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Regulus Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Regulus Therapeutics shares which would translate to 0.534 fractional shares of Regulus Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Regulus Therapeutics, in just a few clicks!

Returns in Regulus Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

Regulus Therapeutics investment value today

Current value as on today

₹1,23,570

Returns

₹23,570

(+23.57%)

Returns from Regulus Therapeutics Stock

₹21,374 (+21.37%)

Dollar Returns

₹2,196 (+2.2%)

Indian investors sentiment towards Regulus Therapeutics

-33%

Period: Sep 21, 2024 to Dec 20, 2024. Change in 30 Days versus previous period

Search volume for Regulus Therapeutics on INDmoney from India has reduced in the last 30 days as on Dec 21, 2024. -33% less investors are searching Regulus Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Regulus Therapeutics

Federated Hermes Inc
19.62%
NEA Management Company, LLC
9.87%
Vivo Capital, LLC
7.63%
Octagon Capital Advisors LP
6.51%
Vanguard Group Inc
6.24%
BlackRock Inc
6.06%

Analyst Recommendation on Regulus Therapeutics

Buy

80%Buy

20%Hold

0%Sell

Based on 10 Wall street analysts offering stock ratings for Regulus Therapeutics(by analysts ranked 0 to 5 stars)

Based on 10 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Regulus Therapeutics

What analysts predicted

Upside of 549.89%

Current:

$1.59

Target:

$10.33

Insights on Regulus Therapeutics

Price Movement
In the last 1 month, RGLS stock has moved up by 13.6%
RGLS vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 35.5% return, outperforming this stock by 7.3%
RGLS vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 23.0% return, outperforming this stock by 78.3%
Price to Sales
ForRGLS every $1 of sales, investors are willing to pay $22.4, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.9 for every $1 of sales.

Regulus Therapeutics Technicals Summary

Sell

Neutral

Buy

Regulus Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Regulus Therapeutics Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Regulus Therapeutics Inc	13.57%	-22.44%	21.37%	-55.22%	-75.81%
Regeneron Pharmaceuticals, Inc.	-5.73%	-34.03%	-17.11%	13.66%	87.56%
Biontech Se	4.48%	30.56%	7.36%	-56.46%	225.6%
Alnylam Pharmaceuticals, Inc.	-0.55%	10.11%	28.49%	30.99%	109.19%
Vertex Pharmaceuticals Incorporated	-11.79%	-16.36%	-1.97%	78.33%	80.59%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Regulus Therapeutics Inc	NA	NA	-0.04	-0.88	-0.72	-0.42	NA	1.33
Regeneron Pharmaceuticals, Inc.	17.51	17.51	1.06	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.17	0.55	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Regulus Therapeutics Inc	Buy	$101.5M	-75.81%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$77.8B	87.56%	17.51	33.61%
Biontech Se	Buy	$26.7B	225.6%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$30.8B	109.19%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$102.1B	80.59%	32.84	-4.51%

About Regulus Therapeutics

regulus therapeutics inc. (nasdaq:rgls) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting micrornas. regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microrna therapeutics pipeline complemented by a maturing micromarkerssm biomarkers platform and a rich intellectual property estate to retain its leadership in the microrna field. regulus is developing rg-101, a galnac-conjugated anti-mir targeting microrna-122 for the treatment of chronic hepatitis c virus infection, and rg-012, an anti-mir targeting microrna-21 for the treatment of alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy. in addition, rg-125, a galnac-conjugated anti-mir targeting microrna-103/107 for the treatment of nash in patients with type 2 diabetes/pre-diabetes, has entered phase i clinical development through its strategic alliance with astrazeneca. reg

Organization	Regulus Therapeutics
Employees	32
CEO	Mr. Joseph P. Hagan M.B.A.
Industry	Health Technology

Management People of Regulus Therapeutics

Name	Title
Mr. Joseph P. Hagan M.B.A.	CEO & Director
Ms. Crispina Calsada CPA	Chief Financial Officer
Mr. Christopher Ray Aker J.D.	Senior VP, General Counsel & Corporate Secretary
Dr. Preston S. Klassen M.D., M.H.S.	President, Head of Research & Development and Director
Mr. Daniel J. Penksa	VP of Finance & Controller
Dr. Claire Susan Padgett M.S., M.T., Ph.D.	Senior Vice President of Clinical Operations
Dr. Rekha Garg M.D., M.S.	Chief Medical Officer
Mr. Edmund Lee Ph.D.	Vice President of Translational Medicine

Important FAQs about investing in Regulus Therapeutics from India :

What is Regulus Therapeutics share price today?

Regulus Therapeutics share price today stands at $1.59, Open: $1.53 ; Previous Close: $1.55 ; High: $1.60 ; Low: $1.51 ; 52 Week High: $3.79 ; 52 Week Low: $1.08. The stock opens at $1.53, after a previous close of $1.55. The stock reached a daily high of $1.60 and a low of $1.51, with a 52-week high of $3.79 and a 52-week low of $1.08.

Can Indians buy Regulus Therapeutics shares?

Yes, Indians can invest in the Regulus Therapeutics (RGLS) from India.

With INDmoney, you can buy Regulus Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Regulus Therapeutics at zero transaction cost.

How can I buy Regulus Therapeutics shares from India?

It is very easy to buy Regulus Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Regulus Therapeutics be purchased?

Yes, you can buy fractional shares of Regulus Therapeutics with INDmoney app.

What are the documents required to start investing in Regulus Therapeutics stocks?

To start investing in Regulus Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.